BHIC BioScience Health Innovations, Inc.
Services-Computer Processing & Data Preparation · OTC · SEC CIK 1784440 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-8.4%
TTM net income YoY-190.2%
TTM EPS YoY-187.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin54.4%
Operating margin-17.4%
Net margin-18.4%
FCF margin—
EBITDA margin—
Returns
ROE-34.5%
ROA-30.3%
ROIC (approx.)-66.0%
Asset turnover1.64x
Leverage & solvency
Liabilities / assets8.8%
Debt / equity0.00x
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.69x
Accruals ratio20.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20222022-08-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $5.69M | $1.84M | $597,595 | $69,343 | $0 |
| Cost of revenue | $2.45M | $536,078 | $113,188 | $9,699 | — |
| Gross profit | $3.24M | $1.31M | $484,407 | $59,644 | — |
| R&D expense | $161,353 | $25,908 | $0 | — | — |
| SG&A expense | $2.21M | $1.15M | $706,257 | $151,319 | $91,921 |
| Operating income | $719,051 | $87,000 | -$251,500 | -$170,450 | -$91,921 |
| Pretax income | — | — | — | — | -$83,208 |
| Income tax | $76,961 | $0 | $0 | $0 | $0 |
| Net income | $642,090 | $87,000 | -$251,500 | -$170,450 | -$83,208 |
| EPS (basic) | 0.06 | 0.01 | -0.01 | — | — |
| EPS (diluted) | 0.06 | 0.01 | -0.01 | — | — |
| Weighted avg. shares (diluted) | 11.40M | 10.90M | 33.76M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $661,925 | $662,517 | $19,238 | $11,569 | $16,253 |
| Receivables | $399,257 | $100,285 | $36,448 | $7,761 | — |
| Inventory | $336,348 | $58,319 | $37,702 | $12,278 | — |
| Current assets | $1.56M | $847,751 | $93,388 | $31,608 | $16,253 |
| Intangibles | $82,887 | $26,037 | $0 | — | — |
| Total assets | $1.71M | $873,788 | $93,388 | $31,608 | $16,253 |
| Total liabilities | $229,851 | $38,548 | $100,148 | $48,791 | $1,860 |
| Shareholders' equity | $1.48M | $835,240 | -$6,760 | -$17,183 | $14,393 |
| Shares outstanding | 10.98M | 10.98M | 40.90M | 5.46M | 5.46M |
| Cash flow statement | |||||
| Operating cash flow | $172,178 | $23,188 | -$307,842 | -$182,779 | -$85,782 |
| Investing cash flow | -$56,850 | -$26,037 | $0 | $0 | — |
| Financing cash flow | -$115,920 | $646,128 | $315,511 | $194,248 | $100,000 |
| Stock-based compensation | — | — | $0 | $225 | — |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.